Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Europe
0
Australia
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Cocaine Muriate
2. Mls001048924
3. Schembl186756
4. Chembl1874133
5. Akos027446592
6. Smr000387112
7. 1089688-45-8
1. Sal De Merck
2. Unii-xh8t8t6wzh
3. Cocaine N-oxide
| Molecular Weight | 339.8 g/mol |
|---|---|
| Molecular Formula | C17H22ClNO4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Exact Mass | 339.1237359 g/mol |
| Monoisotopic Mass | 339.1237359 g/mol |
| Topological Polar Surface Area | 55.8 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 432 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 4 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Certificate Number : R1-CEP 1996-051 - Rev 05
Issue Date : 2016-12-19
Type : Chemical
Substance Number : 73
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-02-23
Pay. Date : 2018-02-05
DMF Number : 20995
Submission : 2007-11-02
Status : Active
Type : II
NDC Package Code : 0406-1520
Start Marketing Date : 2013-12-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16579
Submission : 2003-05-09
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29120
Submission : 2017-08-04
Status : Inactive
Type : II

NDC Package Code : 38779-0723
Start Marketing Date : 2015-07-16
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING

NDC Package Code : 49452-2177
Start Marketing Date : 1997-06-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Numbrino (Cocaine HCl) is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anesthesia, Local.
Lead Product(s): Cocaine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Numbrino
Study Phase: Phase IIIProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cocaine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety, and Tolerability of GOPRELTO and NUMBRINO in Pediatric Nasal Procedures
Details : Numbrino (Cocaine HCl) is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anesthesia, Local.
Product Name : Numbrino
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Numbrino™ (Cocaine Hydrochloride Nasal Solution) company's branded topical anesthetic product for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.
Lead Product(s): Cocaine Hydrochloride,Inapplicable
Therapeutic Area: Neurology Brand Name: Numbrino
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cocaine Hydrochloride,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lannett Receives Fda Approval To Manufacture Numbrino® At Seymour Plant
Details : Numbrino™ (Cocaine Hydrochloride Nasal Solution) company's branded topical anesthetic product for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults.
Product Name : Numbrino
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2022

Details:
Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Otorhinolaryngologic Diseases.
Lead Product(s): Cocaine Hydrochloride,Inapplicable
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2021

Lead Product(s) : Cocaine Hydrochloride,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety, and Tolerability Study of GOPRELTO® Nasal Solution
Details : Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Otorhinolaryngologic Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
EMB-001 is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.
Lead Product(s): EMB-001,Cocaine Hydrochloride,Sodium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Steroid
Sponsor: National Institute on Drug Abuse
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 05, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : EMB-001,Cocaine Hydrochloride,Sodium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : National Institute on Drug Abuse
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine
Details : EMB-001 is a Steroid drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cocaine-Related Disorders.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 05, 2016

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otorhinolaryngologic Diseases.
Lead Product(s): Cocaine Hydrochloride,Inapplicable
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cocaine Hydrochloride,Inapplicable
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia
Details : Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Otorhinolaryngologic Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
RBP-8000 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Related Disorders.
Lead Product(s): RBP-8000,Cocaine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 03, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RBP-8000,Cocaine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RBP-8000 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Opioid-Related Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 03, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Lead Product(s): Cocaine Hydrochloride
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2012

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cocaine Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia
Details : Cocaine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2012

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
84
PharmaCompass offers a list of Cocaine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cocaine Hydrochloride manufacturer or Cocaine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cocaine Hydrochloride manufacturer or Cocaine Hydrochloride supplier.
A Sal De Merck manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sal De Merck, including repackagers and relabelers. The FDA regulates Sal De Merck manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sal De Merck API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sal De Merck manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Sal De Merck supplier is an individual or a company that provides Sal De Merck active pharmaceutical ingredient (API) or Sal De Merck finished formulations upon request. The Sal De Merck suppliers may include Sal De Merck API manufacturers, exporters, distributors and traders.
click here to find a list of Sal De Merck suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Sal De Merck DMF (Drug Master File) is a document detailing the whole manufacturing process of Sal De Merck active pharmaceutical ingredient (API) in detail. Different forms of Sal De Merck DMFs exist exist since differing nations have different regulations, such as Sal De Merck USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sal De Merck DMF submitted to regulatory agencies in the US is known as a USDMF. Sal De Merck USDMF includes data on Sal De Merck's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sal De Merck USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sal De Merck suppliers with USDMF on PharmaCompass.
A Sal De Merck CEP of the European Pharmacopoeia monograph is often referred to as a Sal De Merck Certificate of Suitability (COS). The purpose of a Sal De Merck CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Sal De Merck EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Sal De Merck to their clients by showing that a Sal De Merck CEP has been issued for it. The manufacturer submits a Sal De Merck CEP (COS) as part of the market authorization procedure, and it takes on the role of a Sal De Merck CEP holder for the record. Additionally, the data presented in the Sal De Merck CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Sal De Merck DMF.
A Sal De Merck CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Sal De Merck CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Sal De Merck suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sal De Merck as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sal De Merck API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sal De Merck as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sal De Merck and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sal De Merck NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sal De Merck suppliers with NDC on PharmaCompass.
Sal De Merck Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sal De Merck GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sal De Merck GMP manufacturer or Sal De Merck GMP API supplier for your needs.
A Sal De Merck CoA (Certificate of Analysis) is a formal document that attests to Sal De Merck's compliance with Sal De Merck specifications and serves as a tool for batch-level quality control.
Sal De Merck CoA mostly includes findings from lab analyses of a specific batch. For each Sal De Merck CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sal De Merck may be tested according to a variety of international standards, such as European Pharmacopoeia (Sal De Merck EP), Sal De Merck JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sal De Merck USP).